Last reviewed · How we verify

Momordica Charantia Extract

Syamsudin Abdillah,Ph.D, Pharm D · Phase 2 active Small molecule

Momordica Charantia Extract is a Small molecule drug developed by Syamsudin Abdillah,Ph.D, Pharm D. It is currently in Phase 2 development. Also known as: 2nd group.

At a glance

Generic nameMomordica Charantia Extract
Also known as2nd group
SponsorSyamsudin Abdillah,Ph.D, Pharm D
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Momordica Charantia Extract

What is Momordica Charantia Extract?

Momordica Charantia Extract is a Small molecule drug developed by Syamsudin Abdillah,Ph.D, Pharm D.

Who makes Momordica Charantia Extract?

Momordica Charantia Extract is developed by Syamsudin Abdillah,Ph.D, Pharm D (see full Syamsudin Abdillah,Ph.D, Pharm D pipeline at /company/syamsudin-abdillah-ph-d-pharm-d).

Is Momordica Charantia Extract also known as anything else?

Momordica Charantia Extract is also known as 2nd group.

What development phase is Momordica Charantia Extract in?

Momordica Charantia Extract is in Phase 2.

Related